naltrexone

  1. Andy

    Protocol Trial registration: Low-dose Naltrexone for Post-COVID Fatigue Syndrome, 2022, Luis Nacul, British Columbia Women's Hospital & Health Centre

    Clinical trial registration. There is a growing number of individuals who do not recover to previous levels of health and function following an acute infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but rather develop what has been referred to as 'Long-COVID'...
  2. M

    Low dose Naltrexone - How might it work biologically in ME/CFS?

    LDN Tlr4 inhibition explanation If LDN works via inhibit glia tlr4, does that mean tlr4 is being activated in the first place? So what was activating? Or can inhibiting tlr4 inhibit the common pathways of other signals? For example il1. Tldr, if glia is activated by il1, can inhibit tlr4...
  3. LarsSG

    Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study, 2022, O'Kelly et al

    Highlights Low dose naltrexone (LDN) is safe to use in patients with long covid (LC). In patients with LC for a median 11 months, LDN reduced symptoms at 2 months. In this cohort, LDN also improved well-being in 6 of 7 parameters at 2 months. Abstract Background Up to 37.7% of patients...
  4. Andy

    Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of [ME/CFS], 2022, Eaton-Fitch et al

    Abstract Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious disorder of unknown aetiology. While the pathomechanism of ME/CFS remains elusive, reduced natural killer (NK) cell cytotoxic function is a consistent immunological feature. NK cell effector functions...
Back
Top Bottom